IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis

2014 ◽  
Vol 165 (4) ◽  
pp. 244-246 ◽  
Author(s):  
Mercè Corominas ◽  
Idoia Postigo ◽  
Victoria Cardona ◽  
Ramon Lleonart ◽  
Lucía Romero-Pinel ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Allergic Reactions ◽  
Ige Mediated

scholarly journals Anaphylaxis to Glatiramer Acetate

2015 ◽  
Vol 8 (1) ◽  
pp. 23-25 ◽  
Author(s):  
By Stefan Wöhrl ◽  
Felix Wantke ◽  
Wolfgang Hemmer
Keyword(s):  
Multiple Sclerosis ◽  
Skin Prick Test ◽  
Glatiramer Acetate ◽  
Intradermal Test ◽  
Positive Skin Prick Test ◽  
Positive Skin ◽  
Prick Test ◽  
Asthma Attack ◽  
Anaphylactoid Reactions ◽  
Ige Mediated

Glatiramer acetate (Copaxone, Teva Pharma) and interferon beta are the two only disease-modifying therapies for multiple sclerosis. Glatiramer acetate is known for frequently simulating mild, anaphylactoid reactions while true, IgEmediated allergic reactions have been hardly reported so far. Herein, we report two females suffering from multiple sclerosis who experienced rapidly aggravating hypersensitivity-reactions upon treatment with glatiramer acetate. Patient one experienced an asthma attack, patient two an exacerbation of her urticaria and angioedema. An IgE-mediated mechanism could be demonstrated by a positive intradermal test to a 1:1000 dilution in the first 31-year old and by a positive skin prick test to a 1:10 diluted skin prick test in the second 32-year old second woman.

scholarly journals Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers

Biomolecules ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 393
Author(s):  
Oliver Neuhaus ◽  
Wolfgang Köhler ◽  
Florian Then Bergh ◽  
Wolfgang Kristoferitsch ◽  
Jürgen Faiss ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Neurotrophic Factors ◽  
Common Symptom ◽  
Mrna Levels ◽  
Open Label ◽  
Immunological Parameters ◽  
Beneficial Effects

Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial effects on MS fatigue. The objective of this study was to correlate clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. In a prospective, open-label, multicenter trial, 30 patients with RRMS and fatigue were treated with GA for 12 months. Inclusion criterion was the presence of fatigue as one of the most frequent and disabling symptoms. Before and during treatment, fatigue was assessed using the Fatigue Severity Scale (FSS), the MS-FSS, and the Modified Fatigue Impact Scale (MFIS). In addition, fatigue and quality of life were assessed using the Visual Analog Scales (VAS). Laboratory assessments included screening of 188 parameters using real-time PCR microarrays followed by further analysis of several cytokines, chemokines, and neurotrophic factors. Fatigue self-assessments were completed in 25 patients. After 12 months of treatment with GA, 13 of these patients improved in all three scales (with the most prominent effects on the MFIS), whereas 5 patients had deteriorated. The remaining 7 patients exhibited inconsistent effects within the three scales. Fatigue and overall quality of life had improved, as assessed via VAS. Laboratory assessments revealed heterogeneous mRNA levels of cytokines, chemokines, and neurotrophic factors. In conclusion, we were not able to correlate clinical and molecular effects of GA in patients with RRMS and fatigue.

scholarly journals Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate

2020 ◽  
Vol 11 ◽  
Author(s):  
Justin M. Honce ◽  
Kavita V. Nair ◽  
Brian D. Hoyt ◽  
Rebecca A. Seale ◽  
Stefan Sillau ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Brain Atrophy ◽  
Multiple Sclerosis Patients

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers

2007 ◽  
Vol 17 (8) ◽  
pp. 657-666 ◽  
Author(s):  
Iris Grossman ◽  
Nili Avidan ◽  
Clara Singer ◽  
Dan Goldstaub ◽  
Liat Hayardeny ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Drug Response

Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis

2000 ◽  
Vol 6 (6) ◽  
pp. 378-381 ◽  
Author(s):  
C S Constantinescu ◽  
P Freitag ◽  
L Kappos
Keyword(s):  
Multiple Sclerosis ◽  
Uric Acid ◽  
Free Radicals ◽  
Glatiramer Acetate ◽  
Serum Levels ◽  
Open Label ◽  
Autoimmune Encephalomyelitis ◽  
Natural Inhibitor ◽  
Endogenous Antioxidant ◽  
Average Serum

Free radicals including peroxynitrite are induced in Multiple Sclerosis (MS). Antioxidant and peroxynitrite inhibitor uric acid (UA), suppresses the MS animal model experimental autoimmune encephalomyelitis (EAE). MS patients have lower average serum UA than controls. An inverse relationship exists between MS and gout. Glatiramer acetate (GA) suppresses EAE and is beneficial in relapsing MS. We investigated serum UA changes during open-label treatment of relapsing MS with GAA. Ten patients (six females, four males, aged 19 to 39 years, mean age 32 years) completed 6 months of GAA (Copaxone® 20 mg s.c. daily). Of these, nine completed 12 months. After 6 months on GAA, serum UA (normal, 173-359 mmol/ml for women, 258-491 mmol/ml for men) increased in nine and marginally decreased (302 to 300 mmol/ml) in a single patient. Mean UA significantly increased from 240 to 303 mol/ml (P=0.0014). At 12 months, UA remained significantly higher than at start (P=0.006) decreasing in only one patient. In contrast, we found no significant UA changes after 6 and 12 months of treatment in 21 MS patients treated with interferon b1-a (Avonex®), or in 11 treated with interferon b1-a (Rebif®), or in five placebo-treated controls. Increasing UA, a natural inhibitor of free radicals, may represent a mechanism of action of glatiramer acetate in MS.

scholarly journals Metabolic response to glatiramer acetate therapy in multiple sclerosis patients

BBA Clinical ◽  
2016 ◽  
Vol 6 ◽  
pp. 131-137 ◽  
Author(s):  
Lidia De Riccardis ◽  
Alessandra Ferramosca ◽  
Antonio Danieli ◽  
Giorgio Trianni ◽  
Vincenzo Zara ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Metabolic Response ◽  
Multiple Sclerosis Patients
Sign in / Sign up

Export Citation Format

Share Document